

DAFTAR PUSTAKA

- Aggen, D. H., Drake, C. G., & Rini, B. I. (2020). Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer - Combination Therapy in the First Line Setting. *Clinical Cancer Research*, clincanres.3323.2019. doi:10.1158/1078-0432.ccr-19-3323
- Antic T, Taxy JB. Partial nephrectomy for renal tumors: lack of correlation between margin status and local recurrence. *Am J Clin Pathol*. 2015;143(5):645-651. doi:10.1309/AJCP7LKLZ8JSJQRG
- Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. *Cancer Treat Rev*. 2017;54:58–67.
- Bhindi B, Wallis CJD, Boorjian SA, et al. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. *BJU Int*. 2018;121(5):684-698. doi:10.1111/bju.14127
- Boussiotis, V. A. (2016). Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. *New England Journal of Medicine*, 375(18), 1767–1778. doi:10.1056/nejmra1514296
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424. doi:10.3322/caac.21492
- Brierley JD, Gospodarowicz MK, Wittekind C. *TNM Classification of Malignant Tumours*, 8th Edition. Wiley-Blackwell; 2017.
- Capitanio U, Suardi N, Matloob R, et al. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). *BJU Int*. 2014;114(2):210-215. doi:10.1111/bju.12508
- Capitanio U, Terrone C, Antonelli A, et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. *Eur Urol*. 2015;67(4):683-689. doi:10.1016/j.eururo.2014.09.027
- Capitanio, U., Bensalah, K., Bex, A., Boorjian, S. A., Bray, F., Coleman, J., ... Russo, P. (2018). Epidemiology of Renal Cell Carcinoma. *European Urology*. doi:10.1016/j.eururo.2018.08.036



- Carlsson, J., Sundqvist, P., Kosuta, V., Fält, A., Giunchi, F., Fiorentino, M., & Davidsson, S. (2019). PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma. *Applied Immunohistochemistry & Molecular Morphology*, 1. doi:10.1097/pai.0000000000000766
- Chipollini J, da Costa WH, Werneck da Cunha I, et al. Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies. *Ther Adv Urol*. 2019;11:1756287219882600. doi:10.1177/1756287219882600
- Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016;17(7):917-927. doi:10.1016/S1470-2045(16)30107-3
- Choueiri, T. K., Fay, A. P., Gray, K. P., Callea, M., Ho, T. H., Albiges, L., ... Signoretti, S. (2014). PD-L1 expression in nonclear-cell renal cell carcinoma. *Annals of Oncology*, 25(11), 2178–2184. doi:10.1093/annonc/mdu445
- Chueh, K.-S., Yeh, H.-C., & Li, C.-C. (2013). A huge renal cell carcinoma: Case report and literature review. *Urological Science*, 24(2), 58–60. doi:10.1016/j.urols.2013.05.001
- De Maeseneer DJ, Delafontaine B, Rottey S. Checkpoint inhibition: new treatment options in urologic cancer. *Acta Clin Belg*. 2017;72(1):24-28. doi:10.1080/17843286.2016.1260890
- Deleuze, A., Saout, J., Dugay, F., Peyronnet, B., Mathieu, R., Verhoest, G., ... Kammerer-Jacquet, S.-F. (2020). Immunotherapy in Renal Cell Carcinoma: The Future Is Now. *International Journal of Molecular Sciences*, 21(7), 2532. doi:10.3390/ijms21072532
- Diaz de Leon A, Pedrosa I. Imaging and Screening of Kidney Cancer. *Radiol Clin North Am*. 2017;55(6):1235-1250. doi:10.1016/j.rcl.2017.06.007
- Erlmeier F, Weichert W, Schrader AJ, et al. Prognostic impact of PD-1 and its ligands in renal cell carcinoma. *Med Oncol*. 2017;34(6):99. doi:10.1007/s12032-017-0961-y
- Erlmeier, F., Hartmann, A., Autenrieth, M., Wiedemann, M., Ivanyi, P., Steffens, S., & Weichert, W. (2016). PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception? *Medical Oncology*, 33(11). doi:10.1007/s12032-016-0833-x
- Gershman B, Moreira DM, Thompson RH, et al. Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score-based Analysis. *Eur Urol*. 2018;73(3):469-475. doi:10.1016/j.eururo.2017.10.020



- Gershman B, Thompson RH, Boorjian SA, et al. Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. *J Urol*. 2018;199(5):1143-1148. doi:10.1016/j.juro.2017.11.114
- Gray, R. E., & Harris, G. T., 2019. Renal Cell Carcinoma: Diagnosis and Management. *Am Fam Physician*. 2019 Feb 1;99(3):179-184.
- He, Q., Wang, H., Kenyon, J., Liu, G., Yang, L., Tian, J., ... Wang, Z. (2015). Accuracy of Percutaneous Core Biopsy in the Diagnosis of Small Renal Masses (≤ 4.0 cm): A Meta-analysis. *International Braz j Urol*, 41(1), 15–25. doi:10.1590/s1677-5538.ibju.2015.01.04
- Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur Urol*. 2014;66(4):704-710. doi:10.1016/j.eururo.2014.05.034
- Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. *Nat Rev Dis Prim*. 2017;3:17009. doi:10.1038/nrdp.2017.9
- Iacovelli, R., Nolè, F., Verri, E., Renne, G., Paglino, C., Santoni, M., ... Porta, C. (2015). Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. *Targeted Oncology*, 11(2), 143–148. doi:10.1007/s11523-015-0392-7
- Janowitz T, Welsh SJ, Zaki K, Mulders P, Eisen T. Adjuvant therapy in renal cell carcinoma—past, present, and future. *Semin Oncol*. 2013;40(4):482-491. doi:10.1053/j.seminoncol.2013.05.004
- Ji, M., Liu, Y., Li, Q., Li, X., Ning, Z., Zhao, W., ... Wu, C. (2016). PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. *Cancer Biology & Therapy*, 17(4), 407–413. doi:10.1080/15384047.2016.1156256
- Jonasch, E., Gao, J., & Rathmell, W. K. (2014). Renal cell carcinoma. *BMJ*, 349(nov10 11), g4797–g4797. doi:10.1136/bmj.g4797
- Kammerer-Jacquet S-F, Deleuze A, Saout J, et al. Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. *Int J Mol Sci*. 2019;20(7). doi:10.3390/ijms20071692
- Kim J. Immune checkpoint blockade therapy for bladder cancer treatment. *Investig Clin Urol*. 2016;57:S98–105.
- Kim KS, Sekar RR, Patil D, et al. Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. *Oncoimmunology*. 2018;7(4):e1413519. doi:10.1080/2162402X.2017.1413519



- Klatte T, Streubel B, Wrba F, et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. *Am J Clin Pathol.* 2012;137(5):761-768. doi:10.1309/AJCPQ6LLFMC4OXGC
- Kokkori I, Manos E, Gkika D, et al. AB 50. Diagnostic value of urine cytology test in differential diagnosis in relapsed lung cancer to renal cell carcinoma. *J Thorac Dis.* 2012;4(Suppl 1):AB50. doi:10.3978/j.issn.2072-1439.2012.s050
- Kreshover JE, Richstone L, Kavoussi LR. Renal cell recurrence for T1 tumors after laparoscopic partial nephrectomy. *J Endourol.* 2013;27(12):1468-1470. doi:10.1089/end.2013.0197
- Kumar, V., & Robbins, S. L. 1. (2017). Robbins basic pathology (10th ed.). Philadelphia, PA: Saunders/Elsevier.
- Lai, H.-C., Lin, J.-F., Hwang, T. I. S., Liu, Y.-F., Yang, A.-H., & Wu, C.-K. (2019). Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword? *International Journal of Molecular Sciences*, 20(9), 2194. doi:10.3390/ijms20092194
- Lai, H.-C., Lin, J.-F., Hwang, T. I. S., Liu, Y.-F., Yang, A.-H., & Wu, C.-K. (2019). Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword? *International Journal of Molecular Sciences*, 20(9), 2194. doi:10.3390/ijms20092194
- Laird A, Choy KCC, Delaney H, et al. Matched pair analysis of laparoscopic versus open radical nephrectomy for the treatment of T3 renal cell carcinoma. *World J Urol.* 2015;33(1):25-32. doi:10.1007/s00345-014-1280-y
- Lane BR, Gill IS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy. *J Urol.* 2010;183(2):473-479. doi:10.1016/j.juro.2009.10.023
- Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. *J Urol.* 2010;183(4):1309-1315. doi:10.1016/j.juro.2009.12.035
- Li P, Wong Y-N, Armstrong K, et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. *Cancer Med.* 2016;5(2):169-181. doi:10.1002/cam4.574
- Ljungberg B, Albiges L, Bensalah K, et al. Renal Cell Carcinoma. In: *EAU Guidelines*. Edn. Presented at the EAU Annual Congress Amsterdam 2020. EAU Guidelines Office, Arnhem, The Netherlands.; 2020.



- Ljungberg B, Albiges L, Bensalah K, et al. Renal Cell Carcinoma. In: EAU Guidelines. Edn. Presented at the EAU Annual Congress Amsterdam 2020. EAU Guidelines Office, Arnhem, The Netherlands.; 2020.
- Massari, F., Santoni, M., Ciccicarese, C., Santini, D., Alfieri, S., Martignoni, G., ... Tortora, G. (2015). PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. *Cancer Treatment Reviews*, 41(2), 114–121. doi:10.1016/j.ctrv.2014.12.013
- Matthew Labriola, Jason Zhu, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, Jiaoti Huang, Rajan T. Gupta, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. *Journal of Clinical Oncology* 2019 37:15_suppl, e14259-e14259
- McDermott DF, Drake CG, Sznol M, et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. *J Clin Oncol Off J Am Soc Clin Oncol*. 2015;33(18):2013-2020. doi:10.1200/JCO.2014.58.1041
- Meskawi M, Sun M, Trinh Q-D, et al. A review of integrated staging systems for renal cell carcinoma. *Eur Urol*. 2012;62(2):303-314. doi:10.1016/j.eururo.2012.04.049
- Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. *J Clin Oncol Off J Am Soc Clin Oncol*. 2015;33(13):1430-1437. doi:10.1200/JCO.2014.59.0703
- Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2018;378(14):1277-1290. doi:10.1056/NEJMoa1712126
- Mouracade P, Chavali JS, Kara O, et al. Imaging strategy and outcome following partial nephrectomy. *Urol Oncol*. 2017;35(11):660.e1-660.e8. doi:10.1016/j.urolonc.2017.06.052
- Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. *F1000Research*. 2018;7:307. doi:10.12688/f1000research.13179.1
- Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. *World J Oncol*. 2020;11(3):79-87. doi:10.14740/wjon1279
- Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P, Barsouk A. Epidemiology of Renal Cell Carcinoma. *World J Oncol*. 2020 Jun;11(3):79-87. doi: 10.14740/wjon1279. Epub 2020 May 14. PMID: 32494314; PMCID: PMC7239575.



- Pastore, A. L., Palleschi, G., Silvestri, L., Moschese, D., Ricci, S., Petrozza, V., Carbone, A., Di Carlo, A. (2015). Serum and Urine Biomarkers for Human Renal Cell Carcinoma. *Disease Markers*, 2015, 1–9. doi:10.1155/2015/251403
- Petros FG, Metcalfe MJ, Yu K-J, et al. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. *World J Urol*. 2018;36(7):1093-1101. doi:10.1007/s00345-018-2241-7
- Powles T, Blank C, Chowdhury S, et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. *Eur Urol*. 2011;60(3):448-454. doi:10.1016/j.eururo.2011.05.028
- Raimondi, A., Sepe, P., Zattarin, E., Mennitto, A., Stellato, M., Claps, M., ... Procopio, G. (2020). Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. *Frontiers in Oncology*, 10. doi:10.3389/fonc.2020.01644
- Rossi, S. H., Prezzi, D., Kelly-Morland, C., & Goh, V. (2018). Imaging for the diagnosis and response assessment of renal tumours. *World Journal of Urology*. doi:10.1007/s00345-018-2342-3
- Ruf, M., Moch, H., & Schraml, P. (2016). PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. *International Journal of Cancer*, 139(2), 396–403. doi:10.1002/ijc.30077
- Shen, M., Chen, G., Xie, Q., Li, X., Xu, H., Wang, H., & Zhao, S. (2020). Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. *Urologia Internationalis*, 1–9. doi:10.1159/000506296
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;70(1):7-30. doi:10.3322/caac.21590
- Signoretti, S., Flaifel, A., Chen, Y.-B., & Reuter, V. E. (2018). Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. *Journal of Clinical Oncology*, JCO.2018.79.225. doi:10.1200/jco.2018.79.2259
- Simmi Patel, Armand Asarian, Philip Xiao, Clear cell papillary renal cell carcinoma: a case report and literature review, *Journal of Surgical Case Reports*, Volume 2019, Issue 6, June 2019, rjz177, <https://doi.org/10.1093/jscr/rjz177>
- Staehler MD, Kruse J, Haseke N, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. *World J Urol*. 2010;28(4):543-547. doi:10.1007/s00345-010-0560-4



- Thompson RH, Atwell T, Schmit G, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. *Eur Urol.* 2015;67(2):252-259. doi:10.1016/j.eururo.2014.07.021
- Wah TM, Irving HC, Gregory W, Cartledge J, Joyce AD, Selby PJ. Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. *BJU Int.* 2014;113(3):416-428. doi:10.1111/bju.12349
- Wahlgren T, Harmenberg U, Sandström P, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). *Br J Cancer.* 2013;108(7):1541-1549. doi:10.1038/bjc.2013.119
- Wang, H., Kadlecsek, T. A., Au-Yeung, B. B., Goodfellow, H. E. S., Hsu, L. Y., Freedman, T. S., & Weiss, A. (2010). ZAP-70: An Essential Kinase in T-cell Signaling. *Cold Spring Harbor Perspectives in Biology*, 2(5), a002279–a002279. doi:10.1101/cshperspect.a002279
- Wein, A. J., Kavoussi, L. R., & Campbell, M. F. 1. (2012). *Campbell-Walsh urology* (10th ed.). Philadelphia, PA: Elsevier Saunders.
- Wein, A. J., Kavoussi, L. R., & Campbell, M. F. 1. (2012). *Campbell-Walsh urology* (10th ed.). Philadelphia, PA: Elsevier Saunders.
- Weinstock, M., & McDermott, D. (2015). Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. *Therapeutic Advances in Urology*, 7(6), 365–377. doi:10.1177/1756287215597647
- Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. *Eur J Surg Oncol.* 2014;40(1):121–7.
- Yeong, J., Zhao, Z., Lim, J. C. T., Li, H., Thike, A. A., Koh, V. C. Y., ... Khor, L. Y. (2020). PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas. *Journal of Clinical Urology*
- Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012). Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. *The Journal of Experimental Medicine*, 209(6), 1201–1217. doi:10.1084/jem.20112741
- Zak, K. M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., ... Holak, T. A. (2015). Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. *Structure*, 23(12), 2341–2348. doi:10.1016/j.str.2015.09.010



- Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. *Int J Radiat Oncol Biol Phys*. 2012;82(5):1744-1748. doi:10.1016/j.ijrobp.2011.02.040
- Zheng, G., Li, H., Li, J., Zhang, X., Zhang, Y., & Wu, X. (2017). Metastatic renal clear cell carcinoma to the rectum, lungs, ilium, and lymph nodes. *Medicine*, 96(1), e5720. doi:10.1097/md.00000000000005720
- Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. *Urol Oncol Semin Orig Investig*. 2017;35(1):14–20.